🇺🇸 FDA
Pipeline program

Anti-CD19 Universal CAR-T Cells injection

GC011-411

Phase 1 mab active

Quick answer

Anti-CD19 Universal CAR-T Cells injection for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia is a Phase 1 program (mab) at Xiyuan Hospital of China Academy of Chinese Medical Sciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Indication
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Phase
Phase 1
Modality
mab
Status
active

Clinical trials